|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:methamphetamine_hydrochloride
|
|
gptkbp:approvedBy
|
gptkb:FDA
1947
|
|
gptkbp:associatedWith
|
gptkb:Adderall
gptkb:Ritalin
gptkb:Vyvanse
|
|
gptkbp:ATCCode
|
N06BA03
|
|
gptkbp:chemicalClass
|
amphetamine
|
|
gptkbp:contraindication
|
gptkb:cardiovascular_disease
glaucoma
hyperthyroidism
history of drug abuse
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:eliminationHalfLife
|
10-12 hours
|
|
gptkbp:form
|
gptkb:tablet
5 mg tablet
|
|
gptkbp:genericName
|
no
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Desoxyn
|
|
gptkbp:legalStatus
|
Schedule II controlled substance (US)
|
|
gptkbp:manufacturer
|
gptkb:Recordati_Rare_Diseases
|
|
gptkbp:mechanismOfAction
|
stimulant
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescribes
|
adults
children
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:riskFactor
|
high potential for abuse
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
addiction
anxiety
weight loss
insomnia
increased blood pressure
|
|
gptkbp:usedFor
|
gptkb:attention_deficit_hyperactivity_disorder
obesity
|
|
gptkbp:bfsParent
|
gptkb:MRK
|
|
gptkbp:bfsLayer
|
5
|